Scholarlink

Background <p>Diffuse large B-cell lymphoma (DLBCL) is an aggressive malignancy with limited therapeutic options in the relapsed or refractory setting. Selinexor, a selective inhibitor of nuclear export targeting XPO1, has demonstrated clinical activity in DLBCL. However, the molecular mechanisms underlying its antitumor effects remain incompletely defined.</p> Methods <p>We evaluated the clinical efficacy of Selinexor in a real-world cohort of lymphoma patients and performed integrative transcriptomic and proteomic analyses in DLBCL cell models representing germinal center B-cell–like (GCB) and non-GCB subtypes. Multi-omics profiling, pathway enrichment analysis, and targeted validation were used to characterize Selinexor-induced molecular alterations.</p> Results <p>Selinexor demonstrated meaningful clinical activity in DLBCL patients. Integrated multi-omics analyses revealed two principal mechanistic programs induced by XPO1 inhibition. First, Selinexor activated a p53-centered transcriptional network, characterized by suppression of key S-phase regulators, including GTSE1, PCNA, PCLAF, and CKS1B, leading to cell-cycle arrest and apoptosis. Second, Selinexor induced a metabolic stress response through downregulation of critical metabolic regulators such as SLC1A5 and RRM2, thereby restricting amino acid uptake and nucleotide biosynthesis. Notably, subtype-specific pathway coordination was observed: GCB models exhibited reciprocal regulation between p53 signaling and metabolic pathways, whereas non-GCB models displayed coordinated pathway activation.</p> Conclusions <p>These findings demonstrate that Selinexor exerts antitumor effects in DLBCL through concurrent activation of p53-mediated tumor suppression and disruption of metabolic homeostasis. The observed subtype-dependent pathway interactions provide mechanistic insight into Selinexor response and suggest potential opportunities for subtype-oriented therapeutic strategies.</p> Trial registration <p>Not applicable.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

A dual-mechanism model of Selinexor in DLBCL: p53 reactivation and metabolic reprogramming

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月19日

查看全文
  • Wenqi Zhang,
  • Lin Shi,
  • Yan Li,
  • Cuiying He,
  • Shuixin Cui,
  • Yueping Liu,
  • Xiaoxiao Wang,
  • Lihong Liu,
  • Yuhuan Gao,
  • Lanping Diao,
  • Lili Wu,
  • Yingzhen Yao,
  • Yi Feng,
  • Xiaolin Wu,
  • Shaoning Yin,
  • Weijing Li,
  • Boning Song,
  • Chen Huang

摘要

Background

Diffuse large B-cell lymphoma (DLBCL) is an aggressive malignancy with limited therapeutic options in the relapsed or refractory setting. Selinexor, a selective inhibitor of nuclear export targeting XPO1, has demonstrated clinical activity in DLBCL. However, the molecular mechanisms underlying its antitumor effects remain incompletely defined.

Methods

We evaluated the clinical efficacy of Selinexor in a real-world cohort of lymphoma patients and performed integrative transcriptomic and proteomic analyses in DLBCL cell models representing germinal center B-cell–like (GCB) and non-GCB subtypes. Multi-omics profiling, pathway enrichment analysis, and targeted validation were used to characterize Selinexor-induced molecular alterations.

Results

Selinexor demonstrated meaningful clinical activity in DLBCL patients. Integrated multi-omics analyses revealed two principal mechanistic programs induced by XPO1 inhibition. First, Selinexor activated a p53-centered transcriptional network, characterized by suppression of key S-phase regulators, including GTSE1, PCNA, PCLAF, and CKS1B, leading to cell-cycle arrest and apoptosis. Second, Selinexor induced a metabolic stress response through downregulation of critical metabolic regulators such as SLC1A5 and RRM2, thereby restricting amino acid uptake and nucleotide biosynthesis. Notably, subtype-specific pathway coordination was observed: GCB models exhibited reciprocal regulation between p53 signaling and metabolic pathways, whereas non-GCB models displayed coordinated pathway activation.

Conclusions

These findings demonstrate that Selinexor exerts antitumor effects in DLBCL through concurrent activation of p53-mediated tumor suppression and disruption of metabolic homeostasis. The observed subtype-dependent pathway interactions provide mechanistic insight into Selinexor response and suggest potential opportunities for subtype-oriented therapeutic strategies.

Trial registration

Not applicable.